Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib in BRAF Mutated Papillary Craniopharyngioma
NCT05525273Phase 2Recruiting
- Start
- Sep 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in Papillary craniopharyngioma (pCP). Primary endpoint: Tumor response at 5 years. Started Sep 2023; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Papillary craniopharyngioma (pCP)
Beyond the preview
Go deeper on NCT05525273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525273.